NCT03441568View on ClinicalTrials.gov

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

August 2, 2019

Study Completion Date

August 2, 2019

Conditions
Atopic Dermatitis
Interventions
DEVICE

Modified Diprobase formulation (BAY987534)

The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.

Trial Locations (1)

WA14 5PF

West Timperley Medical Centre, Altrincham

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY